Results of the finished projects

Findings of  research projects

We research to offer new analytical solutions in the field of quality control and the screening and identification of compounds.

NEW ANTI-CANCER DRUGS: DEVELOPMENT OF THERAPIES AIMED AT DIFFERENT TARGET SITES AND COMBINED TREATMENTS

Execution period:  February 2016 – January 2018

Current status:  Finished

Objective of the project: To search for new drugs for the treatment of cancer by developing therapies aimed at different drug target sites and combined treatments:

  • To develop new androgen receptor antagonists that are effective in animal models of prostate cancer and nominate a preclinical candidate.
  • To develop new modulators of protein-protein interactions of the Bcl-2 family effective in animal models of cancer.
  • To discover new inhibitors of ALK5 kinase (Activin receptor-Like Kinase) and TGF-beta signalling pathway effective in animal models of cancer.
  • To discover new JAK (Janus Kinase) kinase inhibitors effective in animal models of myeloproliferative, haematological or solid tumour diseases.
  • To develop new types of nanomaterials that present antitumour activity with low toxicity and/or that enhance the action of antitumour medications directed against DNA.
  • To study the synergy of these different mechanisms of action to treat different types of cancers in vitro and in vivo.
  • To develop highly selective and sensitive analysis methods based on mass spectrometry–liquid chromatography technique, that allow the concentrations of developed chemical compounds and their metabolites to be measured both in plasma and in tumours. In addition, biomarkers will be identified by applying high-resolution mass spectrometry-based proteomics techniques and tools.

Findings obtained:

  • Potent and patentable inhibitors of ALK5 have been identified. The pharmacokinetic properties of the best inhibitors identified in ALK5 have been characterised.
  • A series of JAK3/TYK2 GI-restricted inhibitors have been developed and patented for IBD-fibrosis-colonic cancer axis, active in a murine model of colitis and which do not present toxicity at high dosing. These products are about to begin their first clinical study at Hospital Sant Pau in Barcelona.
  • A series of systemic JAK3/TYK2 inhibitors for psoriasis has been developed and patented. These products are powerful and selective, and their properties make them especially interesting for oral and topical treatment.
  • A number of AR+GR antagonists for prostate cancer have been developed and patented that could enhance current enzyme treatments.
  • Nonsteroidal RBC antagonists have been identified as immune system activators with potential for the treatment of colon cancer.
  • A potential synergy of ALK5 inhibitors discovered by GalChimia with JAK antagonists discovered by Oncostellae has been identified.
  • An effective method for the synthesis of AQCs of different sizes has been successfully developed.
  • It has been proven that smaller AQCs increase the accessibility of chromatin in proliferating cells, enhancing the effect of drugs whose target is DNA, which could improve the efficacy of current treatments.
  • It has been proven that larger AQCs have the ability to cross the blood-brain barrier to reach and reduce metastases, constituting an innovative tool to solve two of the main problems in cancer treatment.
  • Highly selective and sensitive analysis methods based on HPLC-MS have been developed to measure the concentrations of the chemical compounds developed and their metabolites, both in plasma and in tumour.
  • Biomarkers have been identified by applying proteomic techniques and tools based on high-resolution mass spectrometry

Total budget of the project: 1.076.339,63 euros

AMSlab would like to thank all the members and collaborators of the Neogalfarm Project for their involvement and teamwork, which have been key to obtaining the findings. Also thank GAIN for its support in fostering cooperation between SMEs and other agents of the Regional Innovation System.

This project has been subsidised by the Galician Innovation Agency (GAIN), through the Conecta Pyme Programme, co-financed by the European Regional Development Fund (Feder) and supported by the Regional Ministry of Economy, Employment and Industry.

NEW ANALYTICAL STRATEGIES AND NEW INSTRUMENTAL AND SYSTEM DEVELOPMENTS FOR THE REGULATORY CONTROL OF COSMETIC AND TEXTILE PRODUCTS.

Execution period: February 2016- November 2018

Current status: Finished

Objective of the Project: Development of advanced analytical solutions for the regulatory control of cosmetic and textile products.

  • Analytical solutions based on advanced instrumental techniques that allow the coverage of more than 3000 regulated chemical substances in cosmetic products.
  • A screening method allowing very rapid detection of substances not authorised for use in cosmetics.
  • Our own methods for microbiological control of cosmetics based on the reaction of the O SCA and the screening of volatile substances of microbial origin.
  • GC-IMS prototype for the development of a methodology for the in situ analysis of textile products.

Findings obtained:

  • We have achieved a portfolio of analytical services for the cosmetic sector, which allows us to cover practically all analyses and validations. In some cases they have even been externally audited by the National Accreditation Entity for accreditation under ISO-17025.
  • The technical feasibility of applying a method of qualitative screening to dozens of banned substances has been demonstrated thanks to the application of high-resolution mass spectrometry technology.
  • The potential and limitations of GC-IMS coupling technology for the in situ chemical analysis of textile products have been assessed and tested experimentally thanks to a prototype resulting from the development of hardware and software carried out.
  • It has been possible to create a stable prototype that can be used to make these developments and it has been possible to identify solvents compatible with this technology to detect arylamines that, due to their chemical characteristics, were not preferential candidates for this technique.
  • A more robust, simple and safe arylamine collection and reduction methodology than the one compatible with its application in mobile environments has been developed, either to be detected using GC-IMS or thin layer chromatography, an alternative technique that has been successfully tested.
  • Indirect screening using GC-IMS of another substance of great interest in textile control, formaldehyde, has been achieved.
  • Where the application of GC-IMS has achieved notable success is in the screening of volatile substances related to microbial contamination of cosmetics, substances that have been identified in this project through GC-MS studies.
  • For microbiological controls in cosmetics, a rapid alternative method for self-monitoring based on the SCA technique has been achieved, which has been adapted to the cosmetic matrices and allows rapid screening of negative (compliant) samples, which are logically the vast majority, so that only samples showing traces of genetic material from bacteria, fungi or yeasts would need to be confirmed with classical methods.

Total budget of the project: 983.549,04 euros.

This project has been subsidised by the Galician Innovation Agency (GAIN) through the Program Connect SME to encourage cooperation between SMEs and other agents in the Regional Innovation System, co-financed by the European Commission. European Regional Development Fund (ERDF) and supported by the Ministry of Economy, Employment and Industry.